NVAX Stock Chart & Stats
$131.22
-$2.38(-1.78%)
At close: 4:00 PM EDT
$131.22
-$2.38(-1.78%)
Day’s Range― - ―
52-Week Range$115.00 - $204.88
Previous CloseN/A
Volume17.00
Average Volume (3M)170.00
Market Cap
$21.22B
Enterprise Value$833.79
Total Cash (Recent Filing)$790.33M
Total Debt (Recent Filing)$295.06M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 06, 2026EPS Estimate
-6.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding164,438,130
10 Day Avg. Volume135
30 Day Avg. Volume170
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$197.66Price Target Upside50.63% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Partner MomentumBroad collaboration footprint with Pfizer, Sanofi and four new MTAs diversifies commercialization paths and monetization levers. Large partners can accelerate development, provide manufacturing/distribution scale, and create multi-year milestone/royalty streams that support durable revenue beyond direct sales.
Strong Cash Runway And Nondilutive InflowsSubstantial cash and receivables plus recent nondilutive draws provide operational runway into 2028, reducing near-term refinancing pressure. This gives time to advance INDs, convert MTAs to licenses and execute cost reductions without immediate equity dilution, supporting medium-term execution.
Reduced Operating Cost BaseSustained cost cuts materially lower the cash burn profile and improve the odds of reaching non‑GAAP profitability by 2028. A smaller, prioritized spend plan increases flexibility to fund late‑stage priorities and partner obligations while preserving capital for key clinical and licensing milestones.
Bears Say
Negative Shareholders' EquityPersistently negative equity signals structural balance‑sheet weakness that limits borrowing options and increases reliance on external financing or partner funding. It heightens dilution risk and constrains strategic flexibility if operating results deteriorate or milestone timing slips over the medium term.
Weak Cash GenerationOngoing negative operating and free cash flow indicate the business currently consumes cash rather than generates it. That sustained burn makes long‑term funding dependent on partners, milestone receipts or capital markets, raising execution risk if partner payments or revenue timing are delayed.
Reliance On Partner ConversionRevenue and milestone realization depend on external partner decisions and successful partner trials. Uncertain MTA→license timing creates lumpy, unpredictable cash inflows, delaying royalties and license fees and making the path to sustained profitability contingent on third‑party execution.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $115.00 and its highest was $204.88 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $21.22B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 06, 2026 which is in 4 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 06, 2026. The company reported -$1.041 earnings per share for the quarter, beating the consensus estimate of -$4.198 by $3.157.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -6.94.
How many shares outstanding does Novavax have?
Novavax has 164,438,130 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$1.041 in its last earnings report, beating expectations of -$4.198. Following the earnings report the stock price went up 18.382%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in MX:NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$197.66 (50.63% Upside)
$197.66 (50.63% Upside)
Blogger Sentiment
Bullish
MX:NVAX Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.32%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all MX:NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$197.66
▲(50.63% Upside)